This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Qin, Z. Articles by Seliger, B. Search for Related Content PubMed PubMed Citation Articles by Qin, Z. Articles by Seliger, B.

Increased Tumorigenicity, but Unchanged Immunogenicity, of Transporter for Antigen Presentation 1-deficient Tumors¹

Institute of Immunology, Universitaetsklinikum Benjamin Franklin, Free University of Berlin, 12200 Berlin, Germany [Z. Q., T. B.]; III. Department of Internal Medicine, Johannes Gutenberg University, 55131 Mainz, Germany [C. Ha., C. Hu., B. S.]; Institute of Immunology, Second Military Medical University, Shanghai 200433, China [X. C.]; and Max Delbrück Center for Molecular Medicine, 13122 Berlin, Germany [T. B.]

The lack of transporter-for-antigen-presentation (TAP)-1 expression by tumor cells prevents the processing and presentation of MHC class I-restricted tumor antigens. This could affect T-cell-dependent tumor immunity in either the priming or the effector phase. We have established TAP1⁺ and TAP1^- tumor cell lines using ras-transformed NIH3T3 fibroblasts. Impaired TAP1 expression by tumor cells increased their tumorigenicity in immunocompetent, but not in T-cell-deficient, mice. For the generation of tumor immunity, TAP1 expression was not necessary on tumor cells used for vaccination. However, in previously immunized mice TAP1⁺ tumor cells were more efficiently rejected than were TAP1^- tumor cells. CD8⁺ T cells infiltrated both TAP1⁺- and TAP1^--challenge tumors and were required for tumor rejection. In mixed tumor/lymphocyte culture, TAP1 expression by tumor cells significantly increased the IFN- production of antigen-specific spleen cells from immunized, but not from naive, mice. Thus, the lack of TAP1 expression did not change the immunogenicity of tumor cells. It may enable tumor cells to escape T-cell recognition during the effector phase of an antitumor immune response.

This article has been cited by other articles:

				B. Chambers, P. Grufman, V. Fredriksson, K. Andersson, M. Roseboom, S. Laban, M. Camps, E. Z. Wolpert, E. J.H.J. Wiertz, R. Offringa, et al. Induction of Protective CTL Immunity against Peptide Transporter TAP-Deficient Tumors through Dendritic Cell Vaccination Cancer Res., September 15, 2007; 67(18): 8450 - 8455. [Abstract] [Full Text] [PDF]

				F. Herrmann, H.-A. Lehr, I. Drexler, G. Sutter, J. Hengstler, U. Wollscheid, and B. Seliger HER-2/neu-Mediated Regulation of Components of the MHC Class I Antigen-Processing Pathway Cancer Res., January 1, 2004; 64(1): 215 - 220. [Abstract] [Full Text] [PDF]

				Z. Qin, J. Schwartzkopff, F. Pradera, T. Kammertoens, B. Seliger, H. Pircher, and T. Blankenstein A Critical Requirement of Interferon {gamma}-mediated Angiostasis for Tumor Rejection by CD8+ T Cells Cancer Res., July 15, 2003; 63(14): 4095 - 4100. [Abstract] [Full Text] [PDF]

				B. Seliger, D. Atkins, M. Bock, U. Ritz, S. Ferrone, C. Huber, and S. Storkel Characterization of Human Lymphocyte Antigen Class I Antigen-processing Machinery Defects in Renal Cell Carcinoma Lesions with Special Emphasis on Transporter-associated with Antigen-processing Down-Regulation Clin. Cancer Res., May 1, 2003; 9(5): 1721 - 1727. [Abstract] [Full Text] [PDF]